|
Indian Pediatr 2009;46: 26 4-265 |
|
Feasibility and Efficacy of
Intraarticular Steroids (IAS) in Juvenile Idiopathic Arthritis
(JIA) |
Sumit Verma, Rajiva Gupta, *
Rakesh Lodha and S K Kabra,
Departments of Pediatrics and Medicine *,
All India Institute of Medical Science,
Ansari Nagar, New Delhi, India.
|
Abstract
Thirteen children with juvenile idiopathic arthritis
(JIA) were treated with intraarticular steroid injection of triamcilone
acetonide as a day care procedure. More than half (53.4%) the children
were free of pain, limp and NSAID’s use, with improvement in functional
score at 12 weeks. No side effects were reported during the period of
the study.
Key words: Intraarticular Steroids
(IAS), Juvenile Idiopathic Arthritis (JIA), Pain, Functional score,
Resource poor setting,
|
Intraarticular steroid (IAS) administration
is a well-established mode of therapy for children with chronic
arthritis(1,2). This study was undertaken to determine the feasibility,
safety, efficacy and outcome of IAS in children with Juvenile Idiopathic
Arthritis (JIA) on ambulatory basis with conscious sedation, in a
restricted resource setting.
Children diagnosed with oligoarticular/ polyarticular
JIA, unresponsive (determined by joint swelling or effusion, or the
limitation of range of motions, tenderness or pain on motion, or warmth)
to 12 weeks of daily oral naproxen (15-20mg/kg/day) and/or weekly oral
methotrexate (10 mg/m 2/week)
were enrolled in the study after obtaining informed written consent.
Children <6 years of age were given sedation with
midazolam (0.1mg/kg/dose) and ketamine (1mg/kg/dose) prior to the
procedure. Continuous pulse oximetry, heart rate, respiratory rate and
non-invasive blood pressure monitoring was done during the procedure, and
then every 15 minutes till the child was awake and fully conscious. Older
children were given IAS under local anesthesia.
The joints were injected with triamcinolone acetonide
(0.5-1mL, 20-40mg) using standard technique(3). The parent and child were
instructed to keep the movement in the particular joint to the least
possible for next 24 hours. Children enrolled in the study were
evaluated for 6 outcome measures at 0, 6, and 12 weeks: pain scale
(0-10)(4); functional score (0-3) questionnaire, with the score for the
desired task given as follows: without any difficulty 0, with some
difficulty 1, with much difficulty 2 and unable to do 3(5); limp; limb
length, mid-thigh and mid-leg circumference (affected lower limbs) at
baseline and repeated at 12 weeks, and NSAID use.
Thirteen children with JIA (12, oligoarticular and 1
polyarticular) were included. The mean age of the study population was
8±3.38 years (range 2-12 years). Boys (n=6, mean age 10.16±0.89
years) and girls (n=7, mean age 6.28±3.42 years) with the mean age
of onset of JIA was 6.67±3.19 years (range 1-11 years) were enrolled.
Eighteen joints were injected in these patients (13 knee, 3 ankle and 2
elbow joints). Two patients had uncontrolled arthritis and were termed
failure of IAS trial at 6 week visit, and subsequently taken off the
study. Four children were lost to follow-up at the end of 12 weeks study
period.
All the patients who responded to treatment showed
significant improvement in pain and functional scores (Table I).
NSAID use at the initiation of the study was 100%(13), 20%(2) at 6 weeks
and none of the patient reported NSAID drug use at 12 weeks, except the
ones who failed IAS trial (n=2). None of the study patients had a
post-injection flare for a period of 6 months. Our results are similar to
that reported by Neidel, et al.(1).
TABLE I
Outcome Parameters on JIA Patients Given Intraarticular Steroids
Outcome
|
0 wks
(n=13) |
6 wks
(n=10) |
12 wks
(n=7) |
Pain scale (0-10) |
5.46±2.03 |
1.85±3.08 |
0 |
Functional score (0-3) |
|
|
|
Dressing and grooming |
0.23±0.59 |
0.1±0.31 |
0 |
Arising |
2.53±1.94 |
0.3±0.67 |
0 |
Eating |
0.76±1.92 |
0.9±2 |
0.42±1.13 |
Walking |
2.07±1.49 |
0.5±0.84 |
0 |
Hygiene |
0.53±0.87 |
0.3±0.67 |
0.14±0.37 |
Reach |
0.53±1.33 |
0.5±1.58 |
0 |
Grip |
0.61±2.21 |
0.8±2.52 |
0 |
Activities |
3.46±3.99 |
2.3±4.94 |
0.28±0.48 |
Limping, n(%) |
12 (92%) |
2 (20%) |
0 |
NSAID use, n(%) |
13 (100%) |
2 (20%) |
0 |
Bulk of muscles (cm) |
|
|
|
Mid-thigh
circumference |
29.4±5.7 |
|
30.14±6.12 |
Mid-leg
circumference |
21.4±3.8 |
|
21.7±4.38 |
Lower limb length (cm) |
|
|
|
Upper leg |
38.1±9.15 |
|
37.8±10.14 |
Lower leg |
29.5±6.51 |
|
29.28±7.56 |
Our study demonstrated that it is feasible and safe to
give intraarticular steroid injection in JIA patients of all age group by
pediatrician using sedation with midazolam and ketamine without
significant side effect. Small patient population and a short follow-up of
3 months were limitation of the study.
References
1. Neidel J, Boehnke M, Kuster RM. The efficacy and
safety of intraarticular corticosteroid therapy for coxitis in juvenile
reumatoid arthritis. Arthritis Rheum 2002; 46: 1620-1628.
2. Cleary AG, Murphy HD, Davidson JE. Intra-articular
corticosteroid injections in juvenile idiopathic arthritis. Arch Dis Child
2003; 88: 192-196.
3. Wise C. Arthrocentesis and injection of joints and
soft tissues. In Harris Jr. ED, Budd RC, Genovese MC, Firestein GS,
Sergent JS, Sledge CB Eds. Kelly’s Textbook of Rheumatology, 7th Ed.,
Elseiver Saunders, Philadelphia, 2005. p. 692-709.
4. McCaffery M, Pasero C. Numeric Pain Scale Rating. In
McCaffery M, Pasero C Eds. Pain: Clinical Manual. 2nd Ed. St. Louis: Mosby
Inc., 1999; p 67.
5. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health
status in children with juvenile rheumatoid arthritis. Arthritis Rheum
1994; 37: 1761-1769.
|
|
|
|